NCT05189509View on ClinicalTrials.gov

EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

December 28, 2022

Conditions
Stroke, Ischemic
Interventions
DRUG

TNK-Tissue Plasminogen Activator

0.25 mg TNK thrombolysis

Trial Locations (1)

110016

Department of Neurology, General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors
lead

General Hospital of Shenyang Military Region

OTHER